卫宁健康（300253）公告，2024年营业收入为27.82亿元，同比下降12.05%。归属于上市公司股东的净 利润为8789.32万元，同比下降75.45%。基本每股收益为0.0408元/股，同比下降75.52%。公司拟向全体 股东每10股派发现金红利0.15元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

Financial Performance - In 2024, the company's operating revenue decreased by 12.05% year-on-year, while the net profit attributable to shareholders dropped by 75.45%[4] - The decline in performance was primarily due to deferred customer demand, delays in bidding processes, and the ongoing upgrade of the new generation product WiNEX, which has not yet converted into significant revenue[4] - The company's operating revenue for 2024 was ¥2,782,240,900.17, a decrease of 12.05% compared to ¥3,163,424,802.81 in 2023[18] - The net profit attributable to shareholders for 2024 was ¥87,893,175.35, down 75.45% from ¥357,959,124.85 in 2023[18] - The company reported a basic earnings per share of ¥0.0408 for 2024, a decline of 75.52% from ¥0.1667 in 2023[18] - The company experienced a significant decline in net profit after deducting non-recurring gains and losses, with a figure of ¥124,179,786.57 in 2024, down 62.66% from ¥332,572,205.54 in 2023[18] - The weighted average return on equity decreased to 1.53% in 2024 from 6.65% in 2023, indicating a decline in profitability[18] - The company reported a net loss in the fourth quarter of 2024, with a net profit attributable to shareholders of -¥66,737,631.33[20] Cash Flow and Investments - The cash flow from operating activities increased by 120.53% to ¥407,530,345.26 in 2024, compared to ¥184,799,838.70 in 2023[18] - The company's total sales, management, and R&D expenses decreased by 17.94% year-on-year, while net cash flow from operating activities increased by 120.53%[55] - The company reported a significant investment loss of ¥48,245,970.27, which accounted for -55.48% of total profit[88] - Investment activity cash inflow decreased by 90.05% to ¥8,952,261.62 in 2024 from ¥90,013,021.46 in 2023[86] - The total investments during the reporting period were ¥10,018,000.00, a significant decrease of 93.63% compared to ¥157,156,300.00 in the same period last year[93] Market and Industry Trends - The software and information technology services industry, in which the company operates, is strongly supported by national policies, with no signs of overcapacity or continuous decline[4] - The software industry in China is projected to grow, with software business revenue expected to reach ¥14 trillion by 2025, averaging over 12% annual growth[28] - The hospital application software market is forecasted to maintain a compound annual growth rate (CAGR) of 11.0% from 2023 to 2028, reaching a total market size of ¥26.58 billion by 2028[29] - The AI electronic medical record system market is projected to grow from $9.58 billion in 2024 to $31.2 billion by 2032, with a compound annual growth rate (CAGR) of approximately 15.9% from 2025 to 2032[30] Risk Management - The company acknowledges potential risks including technology and product development risks, talent loss risks, industry competition risks, and management risks[5] - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute profit forecasts or commitments to investors[5] - Increased industry competition poses a risk, necessitating proactive management measures and increased R&D investment to maintain competitive advantages[113] - Talent retention is critical, as the software industry faces high turnover rates, and the loss of key personnel could impact the company's innovation and competitiveness[113] Research and Development - R&D investment reached 562 million yuan, accounting for 20.21% of operating revenue, with 98 new patents obtained during the reporting period[58] - The company is currently developing five major R&D projects aimed at enhancing its product line and market competitiveness[80] - The company has obtained over 1,500 software copyright certificates, reflecting its commitment to R&D and technological innovation[53] - The company deployed AI applications and large models for over 20 users by the end of 2024, with an additional 80 users added in the first quarter of 2025[59] Governance and Compliance - The financial report has been verified by the board of directors and senior management, ensuring its accuracy and completeness[4] - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations, and maintaining a robust governance structure[124] - The company has established specialized committees under the board to improve governance and operational oversight[124] - The company is committed to providing equal treatment to all shareholders during meetings, ensuring their rights are upheld[124] Shareholder Returns - The company has proposed a profit distribution plan, offering a cash dividend of 0.15 yuan per 10 shares (tax included) to all shareholders[6] - The company implemented a cash dividend of ¥42.92 million and repurchased shares worth ¥79.99 million to enhance shareholder returns[64] - The company approved a cash dividend of RMB 0.20 per 10 shares (including tax) for the 2023 profit distribution plan, with a total cash dividend amounting to RMB 32,963,566.41[162] - The total cash dividend, including other methods such as share repurchase, reached RMB 112,953,561.93, representing 100% of the profit distribution total[164] Employee Management - The total number of employees at the end of the reporting period is 5,679, with 3,327 in the parent company and 2,352 in major subsidiaries[156] - Employee compensation accounted for 50,352.10 million yuan, representing 31.03% of the company's operating costs for the current period[158] - The company has established a comprehensive training system, including the WiN Academy, which offers various training programs to enhance employee skills and cultural identity[159] - The company has implemented a performance-based compensation system to ensure internal equity and external competitiveness in employee salaries[158] Strategic Initiatives - The company continues to focus on maintaining its core competencies and exploring market expansion opportunities[4] - The company is actively expanding its market presence through localized services and centralized management, enhancing customer engagement and service efficiency[53] - The company plans to expand its market presence with new product launches and technological innovations, targeting a 66% increase in operational efficiency by the end of 2024[100] - The company aims to enhance its digital management capabilities, with a focus on supply chain optimization and resource allocation[101]

证券代码：300253 证券简称：卫宁健康 公告编号：2025-018 卫宁健康科技集团股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）第六届董 事会第十二次会议审议通过了《关于提请召开公司 2024 年度股东大 会的议案》，决定于 2025 年 5 月 12 日（星期一）下午 14:30 召开 2024 年度股东大会。现将有关情况通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第六届董事会第十二次会议 审议通过了《关于提请召开公司 2024 年度股东大会的议案》。本次股 东大会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》等规定。 4、会议时间： （1）现场会议时间：2025 年 5 月 12 日（星期一）14:30 （2）网络投票时间：2025 年 5 月 12 日，其中： ①通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 ...

一、会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关 于公司 2024 年度监事会工作报告的议案》。 证券代码：300253 证券简称：卫宁健康 公告编号：2025-012 卫宁健康科技集团股份有限公司 第六届监事会第十一次会议决议公告 本议案尚需提交公司股东大会审议。 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日在公司会议室以现场方式召开第六届监事会第十一次会议。 会议通知于 2025 年 4 月 7 日以专人送达及电子邮件方式发出。会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席李琳女士主 持。本次监事会的召集和召开符合《中华人民共和国公司法》和《公 司章程》的规定。经全体监事表决，形成决议如下： 二、会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关 于公司 2024 年度财务决算报告的议案》。 本议案尚需提交公司股东大会审议。 《2024 年度财务决算报告》详见中国证监会指定的创业板信息 披露网站。 三、会议以 3 票同意、0 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-011 卫宁健康科技集团股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日在公司会议室以现场和通讯相结合的表决方式召开了第 六届董事会第十二次会议。会议通知于 2025 年 4 月 7 日以专人送达 或电子邮件方式发出。会议应出席董事 7 人，实际出席董事 7 人。本 次董事会的召集和召开符合《中华人民共和国公司法》和《公司章程》 的规定。会议由董事长周炜主持，公司监事及高级管理人员列席了本 次董事会。经全体董事表决，形成决议如下： 一、会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关 于公司 2024 年度总经理工作报告的议案》。 二、会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关 于公司 2024 年度董事会工作报告的议案》。 公司独立董事王蔚松、冯锦锋、俞建春、姚宝敬（届满离任）分 别向董事会递交了《2024 年度独立董事述职报告》，并 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第六届董事会第十二次会议，审议通过了《关于公司 2024年度利润分配预案的议案》，本议案尚需提交公司股东大会审议。 现将具体情况公告如下： 证券代码：300253 证券简称：卫宁健康 公告编号：2025-014 卫宁健康科技集团股份有限公司 关于 2024 年度利润分配预案的公告 3、现金分红方案合理性说明 1、本年度现金分红方案未触及其他风险警示情形 项目 2024 年 2023 年 2022 年 现金分红总额（元） 32,963,566.41 42,916,429.92 21,334,805.48 回购注销总额（元） 79,989,995.52 0.00 0.00 归属于上市公司股东的净利 润（元） 87,893,175.35 357,959,124.85 108,640,078.35 研发投入（元） 562,232,754.81 697,293,644.16 625,518,769.72 营业收入（元） 2,782,240 ...

Core Insights - The core viewpoint of the articles emphasizes the significance of smart hospitals, which leverage advanced technologies such as cloud computing, big data, IoT, mobile internet, and artificial intelligence to enhance healthcare services and management efficiency [1][2][10]. Industry Overview - Smart hospitals integrate various technologies to create a connected and intelligent healthcare environment, optimizing medical resources and improving patient care [2][3]. - The market size for smart hospitals in China is projected to grow from 1.058 billion yuan in 2019 to 10.248 billion yuan in 2024, with an expected reach of 17 billion yuan by 2025 [10]. Industry Development Status - The healthcare sector in China is evolving from providing singular medical services to comprehensive health management platforms, driven by increasing patient demands and technological advancements [8][10]. - The construction of smart hospitals is crucial for the high-quality development of public hospitals and the reform of the healthcare system [10]. Industry Development Trends - The construction of smart hospitals is becoming essential for hospital transformation, requiring top-level planning, data integration, information security, and innovation [25]. - Future advancements in technology will further enhance the quality of medical services and improve patient experiences [25]. Industry Competitive Landscape - Key players in the smart hospital solutions market include companies like Weining Health, Shenzhen BlueLing Software, and several others, focusing on providing integrated digital solutions for healthcare [18][21][23]. - The industry is characterized by a variety of operational models, including single hospitals, multi-site management, and cloud-based smart hospitals, each tailored to specific organizational needs [5][7]. Industry Value Chain - The upstream of the smart hospital industry involves hardware like medical devices and software technologies such as AI, big data, and IoT, while the midstream focuses on solution integration, and the downstream includes application scenarios in various healthcare institutions [12].

Investment Rating - The report gives an investment rating of "Positive" for the AI industry [5] Core Insights - The first general-purpose AI agent, Manus, was launched by the Chinese startup Monica on March 6, 2025, achieving state-of-the-art performance in GAIA benchmark tests, surpassing similar products from OpenAI [1][13] - Manus utilizes a Multiple Agent architecture to efficiently handle complex tasks by breaking them down into planning, execution, and verification modules, operating in independent virtual machines [22] - DeepSeek's R1 version introduces significant algorithmic innovations that enhance reasoning capabilities while reducing computational costs, benefiting small and medium-sized enterprises in the AI industry [2][34] - The report suggests focusing on investment opportunities in AI applications, particularly in AI voice (iFlytek), financial IT (Hang Seng Electronics), medical IT (Weining Health), and AI video/image creation (Wanjing Technology) [3][48] Summary by Sections Section 1: Launch of Manus - Manus is the world's first general-purpose AI agent capable of addressing various complex tasks, including market research, document processing, personalized travel planning, and professional data analysis [10][20] - Manus has demonstrated superior performance compared to OpenAI's Operator in various tasks, showcasing its robust tool-calling capabilities and independence in task execution [22][26] Section 2: DeepSeek's Algorithm Innovations - DeepSeek's R1 version employs a simplified reward design to optimize reasoning capabilities, significantly improving model performance with minimal labeled data [34][36] - The R1-Zero training method has shown a remarkable increase in accuracy, achieving a 71.0% success rate in the AIME competition, indicating a substantial enhancement in reasoning abilities [40][46] Section 3: Investment Recommendations - The report recommends monitoring investment opportunities in AI applications, highlighting key companies such as iFlytek, Hang Seng Electronics, Weining Health, and Wanjing Technology, with projected profit growth in the coming years [3][49]

本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300253 证券简称：卫宁健康 债券代码：123104 债券简称：卫宁转债 2、票面金额：100 元/张，转股价格：17.45 元/股 证券代码：300253 证券简称：卫宁健康 公告编号：2025-010 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于 2025 年第一季度可转换公司债券转股情况的公告 3、2025 年第一季度，共有 50 张"卫宁转债"完成转股,转换成 公司股票 286 股。 4、截至 2025 年 3 月 31 日，"卫宁转债"余额 9,699,483 张。 5、转股期限：2021 年 9 月 22 日至 2027 年 3 月 15 日 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易 所可转换公司债券业务实施细则》的有关规定，卫宁健康科技集团股 份有限公司（以下简称"公司"）现将 2025 年第一季度可转换公司 债券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债基本情况 1、可转债发行上市情况 经中国证 ...

天眼查资料显示，卫宁健康科技集团股份有限公司，成立于2004年，位于上海市，是一家以从事互联网 和相关服务为主的企业。企业注册资本216035.3596万人民币，实缴资本215230.8473万人民币。通过天 眼查大数据分析，卫宁健康科技集团股份有限公司共对外投资了50家企业，参与招投标项目5000次，财 产线索方面有商标信息70条，专利信息461条，此外企业还拥有行政许可19个。 专利摘要显示，本申请提供了一种医学指标趋势图展示方法、计算机设备以及存储介质，涉及数据处理 技术领域，其中，该方法包括：响应针对目标患者的医学指标查询触发操作，获取目标患者针对目标医 学指标的历史医学指标数据集，根据多条历史医学指标的最小报告日期和最大报告日期，在预设坐标系 上绘制用于表示时间的第一坐标轴的起始坐标位置和结束坐标位置，确定各条历史医学指标对应的标注 坐标位置，在预设坐标系上绘制各条历史医学指标的标注点；将多条历史医学指标的标注点进行连线， 生成并展示目标患者针对目标医学指标的指标趋势图。本申请根据目标医学指标的报告日期生成指标趋 势图，提高对患者诊断的准确性。 金融界2025年3月29日消息，国家知识产权局信息显示 ...